Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. on September 16, 2014. The report discloses corporate governance changes, specifically the election of a new director. Note: The request metadata references "Larimar Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Zafgen, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
- Board Election: On September 16, 2014, Frances K. Heller was elected to the Board of Directors as a Class II director.
- Committee Appointment: Ms. Heller was appointed to the Audit Committee.
- Term: Her term will last until the 2016 annual meeting of stockholders or until a successor is elected.
Management Commentary and Risks
Director Background: Ms. Heller previously served as a director from October 2011 to December 2012. Her recent experience includes serving as Senior Vice President of Business Development at Bristol-Myers Squibb, Executive Vice President at Exelixis Pharmaceuticals, and Head of Strategic Alliances at Novartis Pharmaceuticals. She currently serves as a Trustee of the Dana Farber Cancer Institute.
Compensation: As a non-employee director, Ms. Heller will receive cash and equity compensation pursuant to the Company's standard program.
Related Party Transactions: The filing states there are no arrangements or understandings regarding her selection and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the registrant name is Zafgen, Inc., not Larimar Therapeutics, Inc.
- Confirm the effective date of the director election (September 16, 2014).
- Review the Company's non-employee director compensation program for specific equity grant details.
- Check subsequent filings for the 2016 annual meeting results regarding Ms. Heller's re-election.